Foto de portada de Sunstone Health
Sunstone Health

Sunstone Health

Investigación biotecnológica

Boston, Massachusetts 652 seguidores

The diagnostic odyssey shouldn’t take seven years. We cut it to twelve weeks.

Sobre nosotros

Stop paying for the chaos. The healthcare status quo is failing families, so we’re here to break it. The current system tells families to be patient while they spend 7 years trapped in a Diagnostic Odyssey. It tells health plans that high-cost claims are just the "cost of doing business." We call that a systemic failure. Sunstone Health doesn't just "analyze data." We use data precision to identify high-need families that the system is ignoring. We take that 7-year odyssey and compress it into 12 weeks of clarity and expert-driven action. Why Sunstone? We’re proven with hundreds of families and a 90% patient opt-in rate. We don’t just offer software; we offer a champion. We deliver life-changing answers for patients and a measurable 3x+ ROI for payers. We are partnering with major U.S. health plans to prove that the ethical choice is the smartest business decision. The system isn't delivering. We are. Stop accepting the chaos. Let us be your warrior.

Sitio web
https://www.sunstonehealth.com/
Sector
Investigación biotecnológica
Tamaño de la empresa
De 2 a 10 empleados
Sede
Boston, Massachusetts
Tipo
Asociación
Fundación
2019
Especialidades
Rare Disease, Precision Medicine, Genetic Data y Clinical Data

Ubicaciones

Empleados en Sunstone Health

Actualizaciones

  • Genetic Disease Diagnoses Take 7 Years on Average. How Sunstone Health Does It in 12 Weeks Families with kids who have genetic diseases spend an average of 7 years searching for a diagnosis. Sunstone Health delivers the same answer in 12 weeks. 𝗦𝗮𝗺𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲. Completely different system. The problem isn't that the medical knowledge doesn't exist. It's that insurance is designed to pay for the next cheapest thing, not the best thing. So families get stuck on what's called the Diagnostic Odyssey: years of appointments, referrals, and tests that slowly inch toward an answer a specialist could have reached far sooner. Sunstone Health fixes the sequence, not the science. We analyze employer claims data the same way a specialist reviews a patient chart, looking for patterns that signal a genetic basis for disease. When we find a match, we immediately escalate that child for advanced evaluation instead of waiting years for the system to catch up. → Claims data identifies the pattern → The child gets escalated for a second or third look → Families get a diagnosis and a treatment plan that works 𝗧𝗵𝗲 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗺𝗼𝗱𝗲𝗹 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝘁𝗼𝗼. Sunstone created a mechanism that lets employers and health plans pay for the best diagnostic path upfront. Families get faster answers. Employers reduce long-term spend. The system works the way it was always supposed to. Seven years compressed into twelve weeks. That's what happens when you stop letting billing logic dictate clinical decisions. Full Video Now Live to Learn More!

    • No hay descripción de texto alternativo para esta imagen
  • A good hospital and a big care team don’t guarantee answers. Families navigating autism, epilepsy, and rare genetic disease can spend years in testing cycles, referrals, and “wait and see” plans, even inside the best institutions in the country. The reality is that most of our healthcare infrastructure is built to react after a diagnosis is obvious, not to proactively surface risk early. Sunstone exists to change that math. We look at the data the system already has and use it to surface kids who are being missed. The goal is simple: get families to clarity faster, while time still matters. Because progress shouldn’t depend on luck, geography, or who happens to notice first.

  • We’re hosting a live Sunstone community session on March 4th. Josh is going to walk through: – Why we moved from TMA to Sunstone and what that unlocked – What our commercial pipeline actually looks like right now – How we’re positioning Sunstone inside the stop loss and employer market – Why serious operators in this space are leaning in Investors like Zain Hasan - 5 exits, 25+ direct startup investments, Chief Growth Officer of a public stop loss MGU, don’t back stories. They back models. His words, not ours: Sunstone can become a category-defining company in this space. That’s the level of thinking driving this next phase. If you’re part of this community and want to understand where this is headed and how we’re bringing a new model to market, join us live. March 4th Noon ET Register here: https://lnkd.in/eiZ37cfP As we move closer to the end of the round, this is one of the best chances to hear directly from Josh and ask questions in real time.

    • No hay descripción de texto alternativo para esta imagen
  • Our mission continues to ring out loud - no patient should have to wait to get the healthcare they deserve! Check out today's article in Reuters to see how our Cofounder and CEO Joshua Resnikoff thinks about aligning incentives to help employers do the right thing (as fast as possible) for their plan members with genetic diseases 🧬 https://lnkd.in/eekXW2yy

  • We're grateful for the conversation with Na-Ri Oh and Ian Wendt. The The RealPharma Podcast took a deep dive into the rare disease diagnostic odyssey and the seven-year average it takes for families to get answers in the U.S. Josh shared why this issue is personal, why the system behaves the way it does, and why we believe insurers and self-funded employers play a much bigger role in early identification than most people realize. We appreciate Na-Ri and Ian for hosting a thoughtful discussion on a topic that deserves more daylight. If you care about how rare disease is diagnosed and paid for in this country, this one is worth a listen. https://lnkd.in/gwrnFywG

    Tackling the rare disease diagnostic odyssey - with Josh Resnikoff https://lnkd.in/gwrnFywG In the U.S., it takes a whopping SEVEN years on average to diagnose a rare disease. For thousands of families, this means a "diagnostic odyssey” that entails countless visits to doctors, financial hardship, and - most importantly - a slowly closing window of opportunity to address a disease in its early stages. To discuss this topic on The RealPharma Podcast, Ian Wendt and I had the great pleasure of welcoming Joshua Resnikoff, founder and CEO of Sunstone Health. Josh and his team are radically compressing this diagnostic odyssey from seven years to twelve weeks by targeting an often overlooked part of the healthcare system - insurers, in this case specifically self-funded insurance plans. Josh knows from his own experience as a rare disease dad how taxing in every respect it is for families to try and navigate the byzantine healthcare system and why it makes more sense to address this issue at a more systemic level. We talked to him about why he decided to focus on employer-sponsored insurance plans, how he aligns financial incentives with clinical outcomes, and why this approach has positive system-wide repercussions. Listen here: https://lnkd.in/gwrnFywG #RareDisease #HealthInsurance #SelfFundedInsurance #DiagnosticOdyssey #SunstoneHealth #RealPharma

  • We just crossed $1.55M raised from 830+ investors. That’s a lot of people paying attention! Parents, operators, clinicians, investors. People who’ve seen how broken this system is and want something better. Sunstone is building the infrastructure to identify medically complex kids earlier and route them to precision care before years are lost. The stop loss market is shifting toward data-driven underwriting and clinical intelligence. We’re positioned at the center of that shift. KingsCrowd gave us a 4.9/5 rating. More importantly, hundreds of people have decided this is worth backing with real dollars. We’re approaching the end of this round. If you’ve been watching from the sidelines, now’s the moment. Join us here: https://lnkd.in/eWYm_uq2

    • No hay descripción de texto alternativo para esta imagen
  • On February 17, we’re opening things up for a LIVE Sunstone Community Meeting. Josh will walk through what we’re building, what we’re seeing from families, employers, and physicians, and how Sunstone is approaching the next phase of growth as we move toward the end of this round. Join us for a clear look at: what we’re learning and where this is headed in 2026 If you’ve been following along, invested already, or are still deciding whether this is something you want to be part of, this is the right place to hear it straight from the source. Feb 17 · 1:00 PM ET Register here: https://lnkd.in/eiZ37cfP We’re closing in on the end of this round, and we wanted to bring the community in before we do.

    • No hay descripción de texto alternativo para esta imagen
  • Thank you to International Business Times for highlighting how we’re bringing precision care to employer reality. How can you focus on your job when you’re wondering if your child has a future? For millions of parents, this isn't a hypothetical, it’s a reality. The diagnostic odyssey is a systemic failure that hurts both families and the employers who support them. Sunstone Health looks at the failure points. For a family, the cost is stolen milestones. For an employer, the cost is an unmanaged liability. We don't do wait and see. We use technology to proactively hunt for the invisible patients hidden in data and compress years of agony into 12 weeks of clarity. We align the business case with the human case because the system won't move at the speed kids need unless we make it. Read the article here: https://lnkd.in/dNQsDxrf

Páginas similares

Financiación

Sunstone Health 1 ronda en total

Última ronda

Otorgar

20.000,00 US$

Ver más información en Crunchbase